MAVENIR
15.12.2022 08:01:32 CET | Business Wire | Press release
Mavenir today announces the completion of radio integration at the Joint European O-RAN and TIP PlugFest, part of the O-RAN Global PlugFest Fall 2022, at the i14yLab in Berlin, hosted by Deutsche Telekom, EANTC and Vodafone. Mavenir validated its massive MIMO (mMIMO) 32TRX Active Antenna Unit (AAU) for open integration with the Keysight Technologies O-RU conformance and certification testing solution.
Mavenir’s OpenBeam mMIMO 32TRX AAU, is a high-performance O-RAN based Radio Unit (O-RU) supporting 400Mhz instantaneous bandwidth and 200 Mhz occupied bandwidth to meet high capacity and RAN sharing use cases. At 16.8kg, utilizing just passive cooling technology, it is one of industry’s lightest AAU, with uncompromising performance delivering 240W output power and high bandwidth. The AAU utilizes Zero-Force Beamforming technology to maximize performance while minimizing interference.
BG Kumar, President of Mavenir’s Access Networks, Platforms and MDE, said, “Mavenir has further strengthened the Open RAN ecosystem by introducing a competitive, high performance 32TRX mMIMO AAU O-RU product. Through the successful integration and testing at the PlugFest in Berlin, Mavenir aims to accelerate the adoption of open, disaggregated and standards-based solutions.”
Mavenir demonstrated the 32TRX AAU at PlugFest using Keysight’s Open RAN Studio Open RAN Distributed Unit (O-DU) emulator, VXT PXI Vector Transceiver, MXA/MXG signal generators, and PathWave Test Automation framework.
The 32TRX mMIMO AAU is part of the OpenBeam portfolio featuring energy efficiency capabilities, delivering savings of over 80% power consumption during idle periods. It also reduces Total Cost of Ownership (TCO) by employing AI/ML based intelligent automation for fault management, beamforming, energy efficiency, load balancing and improved network performance when used as part of Mavenir’s Open vRAN Solution. Initial 32TRX mMIMO AAU products launched this year cover 3.3GHz to 3.8GHz, targeting Europe, the Americas, and South-East Asia.
In addition to the massive MIMO AAU showcased for integration at the PlugFest, the OpenBeam O-RU portfolio also includes mmWave AAUs and multi-band RRUs for improved network capacity. The OpenBeam O-RUs are available across all frequency bands and can be used for a wide range of use cases, including enterprise and public networks for urban or rural environments.
Mavenir’s participation at the PlugFest builds upon ongoing engagements and progresses current activity in the region. Earlier in the year, Mavenir expanded its European capabilities with the establishment of an Open RAN Centre of Excellence in Germany, strengthening Mavenir’s multinational organisation by delivering regional focus, driving the knowledge and innovation across the region.
About Mavenir
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers and Enterprises in over 120 countries, which serve more than 50% of the world’s subscribers.
i14yLab
The i14y Lab is an open lab for interoperability testing of disaggregated telco systems, such as Open RAN. The lab is operated by a consortium of strong academic and industry partners led by Deutsche Telekom and supported with funding from the German Ministry of Digital and Transport (BMDV).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221214005908/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom